ChinaBio Today -- NeoStem, Inc. priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. NeoStem said it would use the proceeds from the offering to build manufacturing and lab facilities in China and the U.S., then to underwrite stem cell-related R&D projects, and finally to develop and license new pharmaceutical products in China. More details...
